Treace Medical Concepts, Inc. · NASDAQ:TMCI
Treace Medical Concepts — Q1 2025 Earnings Presentation
22 slides from Treace Medical Concepts's earnings presentation, May 8, 2025
Slide 1: On solid footing for sustained growth
On solid footing for sustained growth Investor Presentation January 2025 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may include forward- looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, strategy and plans, industry environm
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures To supplement the financial results presented in accordance with GAAP, this presentation presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expens
Slide 4: Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc. Focused Experts Strong Growth Poised for Acceleration Medical Device company FY 2024 preliminary Expanding comprehensive focused on the surgical revenue of $209.0M to bunion portfolio treatment of bunions and $209.4M (+12% YOY growth related deformities at midpoint)* 10
Slide 5: A large, underserved market
Bunions affect ~1 in 4 U.S. adults¹, a population of 65 million A LARGE, 10,000+ U.S. bunion surgeons underserved 450k annual surgical procedures2: $2.3B current market $5B+ U.S. market opportunity 650k more in need of surgery: $3.3B market Emily Lapiplasty® patient (1) Nix S, et al. J Foot Ankle Re
Slide 6: Bunions: 3-Plane Deformities
Bunions: 3-Plane Deformities An unstable joint in the middle of the foot allows the metatarsal In nearly 90% of bunions, the metatarsal bone to shift outward… bone is rotated in the frontal plane1 Creating the painful “bump” on the side of the big toe Bunion (bump) presents here Transverse Plane Sa
Slide 7: Traditional 2D Surgical Approaches Have Significant Shortcomings
Traditional 2D Surgical Approaches Have Significant Shortcomings 2D OSTEOTOMY (~70% of cases) Cuts the metatarsal Relatively straightforward procedure bone and shifts the Unstable joint Doesn’t address the unstable joint unaddressed bump inward Increased recurrence risk1 2D LAPIDUS FUSION (~30
Slide 8: Lapiplasty 3D Bunion Correction
Lapiplasty 3D Bunion Correction ® ® Treace has democratized a 3D Lapidus bunion procedure, making it accessible to more Our patented 3D solution: physicians and their patients Correct. Cut. Compress. Fixate. Make correction Perform precision Achieve controlled Apply multiplanar fixation before you c
Slide 9: Compelling outcomes supported by differentiated clinical data
Compelling outcomes supported by differentiated clinical data 2025 vs. 2024 3 to 4-year results demonstrate MEDICARE OPPS $12,879 +89% REIMBURSEMENT ASC $9,820 +100% EARLY WEIGHT BEARING in 8.4 days (avg)1,2 ALIGN3D Multicenter Prospective Study1 7 centers, 13 surgeons, 173 patient report, average f
Slide 10: Poised for acceleration
Poised for acceleration Expanding comprehensive bunion portfolio 10 new product launches in 2H 2024 & 2025 Addressing all bunion types with new platforms and technologies 10 10
Slide 11: Comprehensively Addressing All Bunion Classes
US Bunion Opportunity - Treace Flagship Platforms Comprehensively Addressing All Bunion Classes Expanding our reach with best-in-class bunion technologies Mild to Moderate Moderate to Severe W/Midfoot Deformity W / Arthritic Great Toe Joint 11
Slide 12: Expanding Our Leadership Position
Expanding US Our Leadership Bunion Opportunity - Treace FlagshipPosition Platforms New 3D Procedures to Accelerate Bunion Market Penetration Mild to Moderate Bunions Mild to Severe Bunions W/Midfoot Deformity W/Arthritic Great Toe Joint Nanoplasty Percuplasty Micro-Lapiplasty® Mini-Adductoplasty Spe
Slide 13: Enabling Platform Technology: IntelliGuide PSI
Enabling Platform Technology IntelliGuide PSI A Personalized Lapiplasty® and Adductoplasty® Experience Intelligent Pre-Op Planning Comprehensive visualization of patient’s unique deformity before surgery Patient-Specific 3D Correction First and only patient-specific cut guides with built-in personal
Slide 14: Enabling Platform Technology: SpeedPlate
Enabling Platform Technology SpeedPlate Rapid Compression Implants Advancing a New Standard in Bone Fusion Fixation SpeedMTP NEW Attractive to Surgeons The strength and stability of a titanium locking plate1 with the speed and SpeedPlate MicroQuad compression benefits of a nitinol staple2 NEW SpeedP
Slide 15: A unique, highly scalable model
A unique, highly scalable model Margin from one procedure pays for our instrument tray Low cost, reusable High margin, sterile instruments implant kits ~130 sellable SKUs facilitate supply chain and inventory Jim management with ~80% gross margin Lapiplasty® patient 15 15
Slide 16: Go-to-Market Strategy
Go-to-Market Strategy Surgeon Education Raise Patient Awareness Direct Sales Channel Outreach Industry’s only direct bunion-focused multi-platforms sales force is a key growth driver Hands-on training events Educate Lapiplasty.com Search for a doctor Schedule an appointment Comprehensive introductor
Slide 17: Introducing Multiple New Bunion-Focused Technologies to Our Growing Base of Customers
Introducing Multiple New Bunion-Focused Technologies to Our Growing Base of Customers 40% 5-year Revenue CAGR¹ Active Surgeons2 Avg. Revenue per Surgeon3 ($ in thousands) 3,135 $66.7 26% 5-year CAGR¹ in Active Surgeons 2 2,387 $59.4 1,275 $45.0 31% of U.S. bunion surgeons using Lapiplasty® procedure
Slide 18: A Step Ahead
Market-capturing momentum A Step Ahead Tom Lapiplasty® patient Revenue¹ ~$209.2 Moderate to Severe All Bunion Classes ($Millions) (Lapidus Fusion) (~450k annual cases) 2024E $187.1 Segment Penetration2 Total Penetration2 2023 $141.8 2024 23.4% 2024 7.0% 2022 $94.4 5.5% 5.5% 2021 2022 18.3% 2022 5.5%
Slide 19: Sustainable Profitability Ahead
Sustainable Profitability Ahead Adj. EBITDA1 ($ in millions) 2024 Adj. EBITDA Loss to improve ~50% compared $2.6 Improved 45% compared to to full-year 2023 2 4Q’23 Q3’ 23 4Q’24E 2 4Q'23 1Q'24 2Q'24 3Q'24 4Q'24 $(5.1) $(8.3) $(8.7) Jen Lapiplasty® patient Expecting breakeven Adj. EBITDA for full-year
Slide 20: Solid footing, setting the pace
Solid footing, setting the pace The Leader in the most Now a comprehensive exciting subsegment of the bunion solutions company foot and ankle market, one of with multiple new the fastest-growing sectors in technologies Orthopaedics¹ Multiple growth drivers: Positioned to deliver Expecting Modest + 1
Slide 21: Treace: A Step Ahead
TREAC=] A Step Ahead.
Slide 22: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 22
Treace Medical Concepts — Q1 2025 Earnings Presentation on 6ix